Targets › LAMP2
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Jun 2028.
Lysosomal membrane glycoprotein which plays an important role in lysosome biogenesis, lysosomal pH regulation and autophagy. Acts as an important regulator of lysosomal lumen pH regulation by acting as a direct inhibitor of the proton channel TMEM175, facilitating lysosomal acidification for optimal hydrolase activity. (UniProt, P13473)
Open in Phaseline: the race on LAMP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals | RP-A501 rAAV9 gene therapy delivering human LAMP2B transgene | LAMP2 | Phase 2 | Danon Disease | Jun 2028 |
Danon Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.